Balloon implant co BioProtect raises $3.5m

Avishay Noam Photo: PR

The Xenia Venture Capital portfolio company raised the money at a company value of $20 million.

Xenia Venture Capital Ltd. (TASE:XENA) has notified the Tel Aviv Stock Exchange (TASE) that its portfolio company BioProtect has raised $3.5 million at a company value of $20 million. Kfar Saba based BioProtect has developed a minimally invasive balloon implant which reduces rectal toxicity in prostate cancer radiation therapy.

"Each year, 250,000 such oncological procedures are performed in the US and Europe representing an immediate market for BioProtect's products," said Xenia CEO Avishay Noam.

After completion of the latest financing round, Xenia will be left with a 22.85% stake in BioProtect, with full dilution.

Xenia expects BioProtect's financing to raise the value of its assets by NIS 4.4 million. Xenia invests in high-tech, medical device and drug development startups. Since its establishment in 2004, Xenia has invested in more than 30 companies which have accomplished major technological and business achievements.

BioProtect founder and CEO Shaul Shohat said, "BioProtect's technological platform is very flexible and can be adapted to other medical applications and procedures that create added value for the company because there is no need for other development expenses. Also in products based on the balloon that we have developed hundreds of successful procedures have been performed on patients so that it has been proven beyond doubt that the product is safe and effective in treating various medical problems."

Published by Globes [online], Israel business news - www.globes-online.com - on April 13, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017 .

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Avishay Noam Photo: PR
Avishay Noam Photo: PR
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017